What is Elevance Health Inc's earnings per share (EPS)?

Elevance Health Inc (ELV) reported diluted earnings per share of $25.21 for fiscal year 2025. This represents a -1.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Elevance Health Inc Financials

ELV

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Elevance Health Inc (ELV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 45/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Elevance Health Inc has an operating margin of 3.6%, meaning the company retains $4 of operating profit per $100 of revenue. This results in a moderate score of 30/100, indicating healthy but not exceptional operating efficiency. This is down from 4.4% the prior year.

Growth

Elevance Health Inc's revenue grew 12.5% year-over-year to $199.1B, a solid pace of expansion. This earns a growth score of 54/100.

Leverage

Elevance Health Inc carries a low D/E ratio of 0.70, meaning only $0.70 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Elevance Health Inc's current ratio of 1.54 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 26/100, which could limit financial flexibility.

Cash Flow

Elevance Health Inc's free cash flow margin of 1.6% results in a low score of 29/100. Capital expenditures of $1.1B absorb a large share of operating cash flow.

Returns

Elevance Health Inc's ROE of 12.9% shows moderate profitability relative to equity, earning a score of 40/100. This is down from 14.5% the prior year.

Altman Z-Score Grey Zone

2.97

Elevance Health Inc scores 2.97, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

5/9

Elevance Health Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.76x

For every $1 of reported earnings, Elevance Health Inc generates $0.76 in operating cash flow ($4.3B OCF vs $5.7B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Safe

5.1x

Elevance Health Inc earns $5.1 in operating income for every $1 of interest expense ($7.2B vs $1.4B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$199.1B

YoY+12.5%

5Y CAGR+13.8%

10Y CAGR+10.4%

Elevance Health Inc generated $199.1B in revenue in fiscal year 2025. This represents an increase of 12.5% from the prior year.

EBITDA

$8.7B

YoY-5.5%

5Y CAGR+4.2%

10Y CAGR+6.3%

Elevance Health Inc's EBITDA was $8.7B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.5% from the prior year.

Net Income

$5.7B

YoY-5.3%

5Y CAGR+3.3%

10Y CAGR+8.2%

Elevance Health Inc reported $5.7B in net income in fiscal year 2025. This represents a decrease of 5.3% from the prior year.

EPS (Diluted)

$25.21

YoY-1.8%

5Y CAGR+6.4%

10Y CAGR+10.9%

Elevance Health Inc earned $25.21 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$3.2B

YoY-30.3%

5Y CAGR-8.6%

10Y CAGR+1.8%

Elevance Health Inc generated $3.2B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 30.3% from the prior year.

Cash & Debt

$9.5B

YoY+14.5%

5Y CAGR+14.0%

10Y CAGR+16.0%

Elevance Health Inc held $9.5B in cash against $30.8B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

221M

YoY-2.9%

5Y CAGR-2.6%

10Y CAGR-1.9%

Elevance Health Inc had 221M shares outstanding in fiscal year 2025. This represents a decrease of 2.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

3.6%

YoY-0.8pp

5Y CAGR-2.1pp

10Y CAGR-2.4pp

Elevance Health Inc's operating margin was 3.6% in fiscal year 2025, reflecting core business profitability. This is down 0.8 percentage points from the prior year.

Net Margin

2.8%

YoY-0.5pp

5Y CAGR-1.8pp

10Y CAGR-0.6pp

Elevance Health Inc's net profit margin was 2.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.5 percentage points from the prior year.

Return on Equity

12.9%

YoY-1.6pp

5Y CAGR-2.2pp

10Y CAGR+2.3pp

Elevance Health Inc's ROE was 12.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$2.6B

YoY-10.2%

5Y CAGR+8.9%

10Y CAGR-1.4%

Elevance Health Inc spent $2.6B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 10.2% from the prior year.

Capital Expenditures

$1.1B

YoY-11.1%

5Y CAGR+0.7%

10Y CAGR+4.6%

Elevance Health Inc invested $1.1B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.1% from the prior year.

ELV Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Revenue	$199.1B+12.5%	$177.0B+3.3%	$171.3B+9.4%	$156.6B+13.0%	$138.6B+33.0%	$104.2B
Cost of Revenue	$21.2B+7.2%	$19.8B+14.2%	$17.3B+32.7%	$13.0B+19.6%	$10.9B+446.9%	$2.0B
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$21.0B+4.8%	$20.0B-0.3%	$20.1B+13.5%	$17.7B+11.2%	$15.9B+19.1%	$13.4B
Operating Income	$7.2B-8.4%	$7.9B-7.5%	$8.5B+2.6%	$8.3B+9.6%	$7.6B+26.0%	$6.0B
Interest Expense	$1.4B+18.3%	$1.2B+15.0%	$1.0B+21.0%	$851.0M+6.6%	$798.0M+7.0%	$746.0M
Income Tax	$1.0B-45.7%	$1.9B+12.1%	$1.7B+0.7%	$1.7B-7.3%	$1.8B+56.7%	$1.2B
Net Income	$5.7B-5.3%	$6.0B-0.1%	$6.0B+1.6%	$5.9B-4.3%	$6.2B+28.1%	$4.8B
EPS (Diluted)	$25.21-1.8%	$25.68+1.8%	$25.22+3.9%	$24.28-2.7%	$24.95+35.1%	$18.47

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$49.7B-1.9%	$50.7B+1.9%	$49.8B+1.8%	$48.9B+7.6%	$45.4B+0.7%	$45.1B+2.8%	$43.9B+3.1%	$42.6B
Cost of Revenue	$5.5B+2.6%	$5.4B+1.6%	$5.3B+6.2%	$5.0B-17.1%	$6.0B+18.0%	$5.1B+5.7%	$4.8B+26.0%	$3.8B
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$5.4B+2.7%	$5.3B+5.5%	$5.0B-5.7%	$5.3B+10.3%	$4.8B-8.8%	$5.3B+4.0%	$5.1B+3.7%	$4.9B
Operating Income	$309.0M-76.1%	$1.3B-46.6%	$2.4B-23.5%	$3.2B+371.0%	$673.0M-52.2%	$1.4B-49.1%	$2.8B-8.3%	$3.0B
Interest Expense	$366.0M+4.3%	$351.0M+2.9%	$341.0M-0.9%	$344.0M+1.2%	$340.0M+13.3%	$300.0M+7.1%	$280.0M+5.7%	$265.0M
Income Tax	-$331.0M-251.1%	$219.0M-60.0%	$548.0M-10.6%	$613.0M+217.6%	$193.0M-47.1%	$365.0M-46.7%	$685.0M-0.7%	$690.0M
Net Income	$547.0M-54.0%	$1.2B-31.8%	$1.7B-20.2%	$2.2B+422.2%	$418.0M-58.9%	$1.0B-55.8%	$2.3B+2.4%	$2.2B
EPS (Diluted)	N/A	$5.32-31.1%	$7.72-19.7%	$9.61	N/A	$4.36-55.7%	$9.85+2.7%	$9.59

ELV Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Total Assets	$121.5B+3.9%	$116.9B+7.3%	$108.9B+6.0%	$102.8B+5.4%	$97.5B+25.8%	$77.5B
Current Assets	$63.0B+6.9%	$58.9B-1.8%	$60.0B+7.9%	$55.6B+8.8%	$51.1B+31.0%	$39.0B
Cash & Equivalents	$9.5B+14.5%	$8.3B+27.0%	$6.5B-11.7%	$7.4B+51.4%	$4.9B-1.2%	$4.9B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$28.3B+0.2%	$28.3B+11.7%	$25.3B+3.8%	$24.4B+0.6%	$24.2B+18.2%	$20.5B
Total Liabilities	$77.5B+2.7%	$75.5B+8.5%	$69.5B+4.7%	$66.4B+8.4%	$61.3B+34.0%	$45.7B
Current Liabilities	$41.0B+1.1%	$40.6B-2.9%	$41.8B+5.3%	$39.7B+13.8%	$34.9B+48.2%	$23.5B
Long-Term Debt	$30.8B+5.4%	$29.2B+25.7%	$23.2B+4.0%	$22.3B+5.6%	$21.2B+18.9%	$17.8B
Total Equity	$43.9B+6.2%	$41.3B+5.1%	$39.3B+8.5%	$36.2B+0.4%	$36.1B+13.8%	$31.7B
Retained Earnings	$35.4B+5.5%	$33.5B+5.7%	$31.7B+7.1%	$29.6B+9.2%	$27.1B+20.2%	$22.6B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$121.5B-1.0%	$122.7B+0.7%	$121.9B+1.9%	$119.7B+2.4%	$116.9B+0.3%	$116.5B+3.1%	$113.0B+1.0%	$111.9B
Current Assets	$63.0B-1.2%	$63.8B+0.7%	$63.3B+3.6%	$61.1B+3.7%	$58.9B-6.2%	$62.8B+0.9%	$62.3B+2.2%	$60.9B
Cash & Equivalents	$9.5B+8.9%	$8.7B+1.8%	$8.6B+14.1%	$7.5B-9.5%	$8.3B+5.4%	$7.9B+21.1%	$6.5B+4.4%	$6.2B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$28.3B-0.4%	$28.5B+0.3%	$28.4B-0.2%	$28.4B+0.5%	$28.3B+8.9%	$26.0B0.0%	$26.0B+0.1%	$25.9B
Total Liabilities	$77.5B-1.5%	$78.7B+0.7%	$78.1B+1.3%	$77.1B+2.2%	$75.5B+3.9%	$72.7B+2.8%	$70.7B-0.7%	$71.2B
Current Liabilities	$41.0B+0.4%	$40.9B-6.7%	$43.8B+2.7%	$42.7B+5.2%	$40.6B-3.5%	$42.0B+0.5%	$41.8B-5.7%	$44.3B
Long-Term Debt	$30.8B-1.2%	$31.2B+10.6%	$28.2B+0.2%	$28.1B-3.8%	$29.2B+18.3%	$24.7B+0.5%	$24.6B+11.8%	$22.0B
Total Equity	$43.9B-0.2%	$44.0B+0.5%	$43.7B+2.9%	$42.5B+2.9%	$41.3B-5.6%	$43.8B+3.8%	$42.2B+3.9%	$40.6B
Retained Earnings	$35.4B-0.5%	$35.6B+0.1%	$35.5B+2.9%	$34.5B+3.0%	$33.5B-4.6%	$35.2B+1.7%	$34.6B+4.5%	$33.1B

ELV Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Operating Cash Flow	$4.3B-26.1%	$5.8B-27.9%	$8.1B-4.0%	$8.4B+0.4%	$8.4B+38.0%	$6.1B
Capital Expenditures	$1.1B-11.1%	$1.3B-3.1%	$1.3B+12.5%	$1.2B+6.0%	$1.1B+0.9%	$1.1B
Free Cash Flow	$3.2B-30.3%	$4.6B-32.7%	$6.8B-6.7%	$7.2B-0.4%	$7.3B+46.0%	$5.0B
Investing Cash Flow	-$1.3B+74.0%	-$5.2B+7.3%	-$5.6B-22.2%	-$4.6B+52.7%	-$9.6B-245.2%	-$2.8B
Financing Cash Flow	-$1.7B-245.7%	$1.2B+135.6%	-$3.3B-154.1%	-$1.3B-411.6%	$423.0M+118.7%	-$2.3B
Dividends Paid	$1.5B+1.4%	$1.5B+8.1%	$1.4B+13.5%	$1.2B+11.3%	$1.1B+35.0%	$818.0M
Share Buybacks	$2.6B-10.2%	$2.9B+8.4%	$2.7B+15.5%	$2.3B+21.9%	$1.9B+11.7%	$1.7B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$84.0M-92.6%	$1.1B-44.7%	$2.1B+102.0%	$1.0B+44.1%	$706.0M-73.6%	$2.7B+498.9%	$447.0M-77.4%	$2.0B
Capital Expenditures	$293.0M-18.6%	$360.0M+34.8%	$267.0M+36.2%	$196.0M-39.1%	$322.0M-3.0%	$332.0M+2.8%	$323.0M+15.8%	$279.0M
Free Cash Flow	-$209.0M-127.0%	$775.0M-56.6%	$1.8B+117.7%	$821.0M+113.8%	$384.0M-83.6%	$2.3B+1791.1%	$124.0M-92.7%	$1.7B
Investing Cash Flow	$464.0M+137.9%	-$1.2B-78.2%	-$687.0M-767.0%	$103.0M+106.3%	-$1.6B-308.5%	-$401.0M+51.0%	-$818.0M+64.6%	-$2.3B
Financing Cash Flow	$236.0M-2.9%	$243.0M+178.9%	-$308.0M+83.9%	-$1.9B-235.6%	$1.4B+253.9%	-$915.0M-237.0%	$668.0M+1987.5%	$32.0M
Dividends Paid	$377.0M-1.0%	$381.0M-1.0%	$385.0M-0.3%	$386.0M+3.5%	$373.0M-1.3%	$378.0M0.0%	$378.0M-0.3%	$379.0M
Share Buybacks	$471.0M-46.2%	$876.0M+131.7%	$378.0M-57.0%	$880.0M-51.4%	$1.8B+2918.3%	$60.0M-87.0%	$463.0M-18.2%	$566.0M

ELV Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	3.6%-0.8pp	4.4%-0.5pp	5.0%-0.3pp	5.3%-0.2pp	5.5%-0.3pp	5.8%
Net Margin	2.8%-0.5pp	3.4%-0.1pp	3.5%-0.3pp	3.8%-0.7pp	4.4%-0.2pp	4.6%
Return on Equity	12.9%-1.6pp	14.5%-0.8pp	15.2%-1.0pp	16.3%-0.8pp	17.1%+1.9pp	15.2%
Return on Assets	4.7%-0.5pp	5.1%-0.4pp	5.5%-0.2pp	5.7%-0.6pp	6.3%+0.1pp	6.2%
Current Ratio	1.54+0.1	1.45+0.0	1.44+0.0	1.40-0.1	1.47-0.2	1.66
Debt-to-Equity	0.700.0	0.71+0.1	0.59-0.0	0.62+0.0	0.59+0.0	0.56
FCF Margin	1.6%-1.0pp	2.6%-1.4pp	4.0%-0.7pp	4.6%-0.6pp	5.3%+0.5pp	4.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	0.6%-1.9pp	2.5%-2.3pp	4.9%-1.6pp	6.5%+5.0pp	1.5%-1.6pp	3.1%-3.2pp	6.3%-0.8pp	7.1%
Net Margin	1.1%-1.2pp	2.3%-1.2pp	3.5%-1.0pp	4.5%+3.5pp	0.9%-1.3pp	2.3%-3.0pp	5.2%-0.0pp	5.3%
Return on Equity	1.3%-1.5pp	2.7%-1.3pp	4.0%-1.2pp	5.1%+4.1pp	1.0%-1.3pp	2.3%-3.1pp	5.5%-0.1pp	5.5%
Return on Assets	0.4%-0.5pp	1.0%-0.5pp	1.4%-0.4pp	1.8%+1.5pp	0.4%-0.5pp	0.9%-1.2pp	2.0%+0.0pp	2.0%
Current Ratio	1.54-0.0	1.56+0.1	1.44+0.0	1.43-0.0	1.45-0.0	1.500.0	1.49+0.1	1.37
Debt-to-Equity	0.700.0	0.71+0.1	0.64-0.0	0.66-0.0	0.71+0.1	0.56-0.0	0.58+0.0	0.54
FCF Margin	-0.4%-1.9pp	1.5%-2.1pp	3.6%+1.9pp	1.7%+0.8pp	0.9%-4.3pp	5.2%+4.9pp	0.3%-3.7pp	4.0%

Similar Companies

$70.5B

$92.2B

$21.2B

$16.7B

$7.1B

Frequently Asked Questions

What is Elevance Health Inc's annual revenue?

Elevance Health Inc (ELV) reported $199.1B in total revenue for fiscal year 2025. This represents a 12.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Elevance Health Inc's revenue growing?

Elevance Health Inc (ELV) revenue grew by 12.5% year-over-year, from $177.0B to $199.1B in fiscal year 2025.

Is Elevance Health Inc profitable?

Yes, Elevance Health Inc (ELV) reported a net income of $5.7B in fiscal year 2025, with a net profit margin of 2.8%.

What is Elevance Health Inc's EBITDA?

Elevance Health Inc (ELV) had EBITDA of $8.7B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Elevance Health Inc have?

As of fiscal year 2025, Elevance Health Inc (ELV) had $9.5B in cash and equivalents against $30.8B in long-term debt.

What is Elevance Health Inc's operating margin?

Elevance Health Inc (ELV) had an operating margin of 3.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Elevance Health Inc's net profit margin?

Elevance Health Inc (ELV) had a net profit margin of 2.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Elevance Health Inc's return on equity (ROE)?

Elevance Health Inc (ELV) has a return on equity of 12.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Elevance Health Inc's free cash flow?

Elevance Health Inc (ELV) generated $3.2B in free cash flow during fiscal year 2025. This represents a -30.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Elevance Health Inc's operating cash flow?

Elevance Health Inc (ELV) generated $4.3B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Elevance Health Inc's total assets?

Elevance Health Inc (ELV) had $121.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Elevance Health Inc's capital expenditures?

Elevance Health Inc (ELV) invested $1.1B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Elevance Health Inc buy back shares?

Yes, Elevance Health Inc (ELV) spent $2.6B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Elevance Health Inc have outstanding?

Elevance Health Inc (ELV) had 221M shares outstanding as of fiscal year 2025.

What is Elevance Health Inc's current ratio?

Elevance Health Inc (ELV) had a current ratio of 1.54 as of fiscal year 2025, which is generally considered healthy.

What is Elevance Health Inc's debt-to-equity ratio?

Elevance Health Inc (ELV) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Elevance Health Inc's return on assets (ROA)?

Elevance Health Inc (ELV) had a return on assets of 4.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Elevance Health Inc's Altman Z-Score?

Elevance Health Inc (ELV) has an Altman Z-Score of 2.97, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Elevance Health Inc's Piotroski F-Score?

Elevance Health Inc (ELV) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Elevance Health Inc's earnings high quality?

Elevance Health Inc (ELV) has an earnings quality ratio of 0.76x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Elevance Health Inc cover its interest payments?

Elevance Health Inc (ELV) has an interest coverage ratio of 5.1x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Elevance Health Inc?

Elevance Health Inc (ELV) scores 45 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.